-

Bruker Announces New D6 PHASERTM Benchtop X-Ray Diffraction (XRD) Platform for Materials Analysis and Advanced Research

KARLSRUHE, Germany--(BUSINESS WIRE)--Bruker Corporation (Nasdaq: BRKR), the global leader in X-ray diffraction, today announces the new D6 PHASERTM X-Ray Diffraction (XRD) system. The D6 PHASER is a new benchtop XRD platform designed with the analytical flexibility typically only available in larger, floor-standing systems. Unlike conventional, more limited benchtop XRD instruments, the D6 PHASER enables analytical methods that go beyond powder diffraction. With its wide range of capabilities, the D6 PHASER will enable more XRD applications for new markets and user communities.

Building on the success of the D2 PHASER, the D6 PHASER combines the functionality of the floor-standing D8 platform with an innovative benchtop design that includes high X-ray excitation power and a versatile set of X-ray optics. The Motorized Air Scatter Screen (MASS) enables Dynamic Beam Optimization (DBO) for optimum performance over the goniometer range. The D6 PHASER can be equipped with a range of sample stages for a large variety of X-ray diffraction applications, including capillary transmission, grazing incidence diffraction, X-ray reflectometry, residual stress, texture analysis, and non-ambient investigations. The DaVinci stage-interface allows swapping sample stages without realignment.

The patented D6 PHASER goniometer provides intrinsic angular accuracy of 0.01° over the 2θ range. With a touch on the integrated panel, the D6 PHASER automatically performs verification of angular accuracy. The D6 PHASER offers the family of LYNXEYETM detectors. For the analysis of non-perfect powder samples, the user can select the patented Bragg2DTM method. The optional LYNXEYE XE-T detector offers proprietary suppression of Cu-Kß reflections without the usual constraints when using a Kß metal filter.

The versatile D6 PHASER combined with DIFFRAC.SUITETM software provides flexibility for automated push-button methods or to customize measurement configurations for optimized data quality. The D6 PHASER needs no external water cooling and has no special electrical requirements for convenience to bring versatile, high-performance XRD to any laboratory. Finally, the D6 PHASER complies with the latest radiation protection and machinery directives, and it is available as a GxP compliant solution.

Dr. Frank Burgaezy, President of the Bruker AXS Division, commented: “Offering unmatched benchtop capabilities, versatility, and a great user experience, the D6 PHASER is an innovative benchtop X-ray diffraction platform to help users answer today’s materials analysis questions and support tomorrow’s advanced materials discoveries.”

The D6 PHASER makes advanced XRD methods accessible for applied markets like clean energy.

Dr. Jan Vos, Researcher at Magneto Special Anodes stated: “We are heavily invested in the development of electrocatalytic coatings that will form the beating heart of the next generation of water electrolyzers in the green energy transition. Bruker's new D6 PHASER platform will provide us with the extraordinary power, flexibility, and accuracy needed to push our coating development forward. We will have access to advanced X-ray techniques crucial for material science that were previously not available in a compact benchtop system. We are looking forward to creating a big push on the market, and the D6 PHASER will no doubt aid us greatly in making this possible.”

For more information about the D6 PHASER, please visit www.bruker.com/d6phaser.

About Bruker Corporation (Nasdaq: BRKR)

Bruker is enabling scientists to make breakthrough discoveries and develop new applications that improve the quality of human life. Bruker’s high performance scientific instruments and high value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular, and microscopic levels. In close cooperation with our customers, Bruker is enabling innovation, improved productivity, and customer success in life science molecular and cell biology research, in applied and pharma applications, in microscopy and nanoanalysis, as well as in industrial applications. Bruker offers differentiated, high-value life science and diagnostics systems and solutions in preclinical imaging, clinical phenomics research, proteomics and multiomics, spatial and single-cell biology, functional structural and condensate biology, as well as in clinical microbiology and molecular diagnostics. Please visit www.bruker.com.

Contacts

Media Contact:
Dr. Heiko Ress
Bruker AXS Director Marketing Communications
T: +(49) 721 50997-0
E: heiko.ress@bruker.com

Investor Relations Contact:
Justin Ward
Sr. Director Investor Relations & Corp Development
T: +1 (978) 313-5800
E: Investor.Relations@bruker.com

Bruker Corporation

NASDAQ:BRKR

Release Versions
$Cashtags
Hashtags

Contacts

Media Contact:
Dr. Heiko Ress
Bruker AXS Director Marketing Communications
T: +(49) 721 50997-0
E: heiko.ress@bruker.com

Investor Relations Contact:
Justin Ward
Sr. Director Investor Relations & Corp Development
T: +1 (978) 313-5800
E: Investor.Relations@bruker.com

Social Media Profiles
More News From Bruker Corporation

Bruker Accelerates the Future of Diagnostic and Prognostic Spatial Proteomics with the Launch of CellScape XR

ORLANDO, Fla.--(BUSINESS WIRE)--Bruker Corporation (Nasdaq: BRKR) announced the launch of CellScape™ XR, a next-generation spatial proteomics platform designed to advance the development of diagnostic and prognostic assays by delivering unprecedented quantitative performance, robustness, and flexibility. CellScape XR addresses a critical bottleneck in translational research by enabling high-throughput, reproducible spatial proteomics at a scale and rigor required for translational and clinical...

Bruker Expands Collaboration with Noetik to Advance Tissue Foundational Models for Translational and Therapeutic Applications

ORLANDO, Fla.--(BUSINESS WIRE)--Bruker Spatial Biology, a division of Bruker Corporation (Nasdaq: BRKR) announced today that it will expand its collaboration with Noetik Inc., following their prior study of more than 3500 patient samples with the CosMx® Spatial Molecular Imager (SMI). CosMx SMI powers Noetik's pre-training and scaling of bio-foundation models to perform complex genome-wide simulations of human cellular- and tissue-level biology to enable diverse therapeutics applications. “Noet...

Bruker Announces Major Advancements at AGBT to Enable Complete High-Fidelity Spatial Biology Across the Biological Spectrum

ORLANDO, Fla.--(BUSINESS WIRE)--Bruker Corporation (Nasdaq: BRKR) announced today significant portfolio advancements from Bruker Spatial Biology to be unveiled at the 2026 Advances in Genome Biology and Technology (AGBT) General Meeting. These updates highlight Bruker’s category leadership in spatial biology and its commitment to delivering best‑in‑class solutions across DNA, RNA, and protein. The Bruker Spatial Biology division will launch several new products, introduce expanded capabilities,...
Back to Newsroom